DL PHARMA +
ActiveThe computed 12-month bankruptcy probability of DL PHARMA + is 2.6% (moderate). The 2025 annual accounts show equity of €11k and a net result of €-14k. Equity is growing by ~10.3% per year across the filed fiscal years. Its solvency ranks better than 65% of 18016 sector peers (fiscal year 2025). The company has been active since 2020 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2025
Axes · tick = 2024
Profitability0▼-100
Solvency94▼-6
Growth32▼-20
Stability94
Bankruptcy probability, 12 months
2.6%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit up to €500 at 30 days acceptable
Liquidity ample (current ratio 1.91 against 3.01 in 2024), and 48.1% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
51.9%
Return on assets
-65.6%
Age of the figures
17 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 31-10-2025, 0 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
on the day
2024
36 d early
2023
4 d early
2022
5 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-03-2026 and is due by 31-10-2026. Nothing is late today.
Companies Code · seven monthsPosition in the running window
31-03-2026 close14-09-2026 today31-10-2026 deadline
Financials · fiscal year 2025, micro schema
Equity
€11k▼ 55.8%
2024 · €25k
2022: €15k
2023: €19k
2024: €25k
2022 → 2025
Total assets
€21k▼ 42.2%
2024 · €37k
2022: €28k
2023: €32k
2024: €37k
2022 → 2025
Net result
€-14k
2024 · €6k
2022: €10k
2023: €5k
2024: €6k
2022 → 2025
Working capital
€9k▼ 60.9%
2024 · €23k
2022: €14k
2023: €18k
2024: €23k
2022 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line2022202320242025Trend
Equity€15k-€19k▲ 32.2%€25k▲ 28.6%€11k▼ 55.8%
Operating result€12k-€6k▼ 50.3%€8k▲ 22.9%€-14k
Net result€10k-€5k▼ 51.1%€6k▲ 17.4%€-14k
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result turns negative in 2025: a loss of €14k after €8k in 2024, the lowest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €21k
Fixed assets
€2k▲ 9.5%
Current assets
€19k▼ 45.1%
Equity and liabilities €21k
Equity
€11k▼ 55.8%
Debt
€10k▼ 13.3%
The debt ratio rises from 32.1% to 48.1%: equity shrinks faster than debt is paid down.
Key figures and ratios
EBITDA
€-13k▼
2024 · €8k
Cash flow
€-13k▼
2024 · €6k
Solvency
51.9%▼
2024 · 67.9%
Current ratio
1.91▼
2024 · 3.01
Quick ratio
1.91▼
2024 · 3.01
Debt / equity
0.93▲
2024 · 0.47
ROE
-126.3%▼
2024 · 22.2%
ROA
-65.6%▼
2024 · 15.1%
Interest coverage
-2840.57▼
2024 · 98.58
Debt
€10k▼
2024 · €12k
Debt ≤ 1 year
€10k▼
2024 · €12k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€37k€21k▼
Fixed assets21/28€2k€2k▲
Tangible fixed assets22/27€2k€2k▲
Furniture and vehicles24€2k€2k▲
Current assets29/58€35k€19k▼
Amounts receivable within one year40/41€8k€10k▲
Trade receivables40€8k€7k▼
Other amounts receivable41€16€2k▲
Cash at bank and in hand54/58€26k€8k▼
Deferred charges and accrued income490/1€1k€854▼
Equity and liabilities
Total equity and liabilities10/49€37k€21k▼
Equity10/15€25k€11k▼
Contributions10/11€5k€5k=
Reserves13€20k€6k▼
Distributable reserves133€20k€6k▼
Amounts payable17/49€12k€10k▼
Amounts payable within one year42/48€12k€10k▼
Trade debts44€3k€3k▼
Suppliers440/4€3k€3k▼
Taxes, remuneration and social security45€7k€6k▼
Taxes450/3€7k€6k▼
Other amounts payable47/48€2k€1k▼
Accrued charges and deferred income492/3€227€200▼
Income statement
Code20242025
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€759€1k▲
Other operating charges640/8€886€742▼
Gross operating margin9900€9k€-12k▼
Operating profit (loss)9901€8k€-14k▼
Financial income75/76B-€0
Recurring financial income75-€0
Financial charges65/66B€85€5▼
Recurring financial charges65€85€5▼
Profit (loss) for the period before taxes9903€8k€-14k▼
Income taxes67/77€2k-
Profit (loss) for the period9904€6k€-14k▼
Profit (loss) for the period to be appropriated9905€6k€-14k▼
Appropriation of the result
Profit (loss) to be appropriated9906€6k€-14k▼
Transfer from equity791/2-€14k
Transfer to equity691/2€6k-
To other reserves6921€6k-
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2025
31-10
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
31-03
Financial
Weakest financial yearnet €-14k ▼351%
Net result drops to €-14k, the lowest in the series.
2024
25-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2023
27-10
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2022
26-10
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
2 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Zulte · 1 establishment unit since 2020
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Boswegel 279870 ZulteGround area
2,535 m²
Building footprint
157 m²
Volume, LiDAR
252 m³
Parcel 44050B0812/00A000, Flanders · tallest building 7.8 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
DL PHARMA +
since 20202.308.133.707
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44050B0812/00A000 | Flanders | 2,535 m² | 1 · 157 m² | 7.8 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Apotheek DC Turnhout
BE 0436.019.057
Turnhout · Eq €11k
AJPhar
BE 0778.569.213
Waterloo · Eq €11k
ALBA2RO
BE 0738.728.937
Gembloux · Eq €11k
Pharmacie du Palais
BE 0899.955.508
Thimister-Clermont · Eq €11k
APOTHEEK PANORAMA BAAL
BE 0722.881.513
Tremelo · Eq €11k
Of 5,208 companies in sector 47730 we hold annual accounts for 3,850. 880 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded28-09-2020
Fiscal year end31-03
Activities, NACEBEL
47730Retail sale of pharmaceutical products
70200Business and other management consultancy
70220Business consulting
82990Other business support services
Sources
Crossroads Bank for EnterprisesNational Bank · 4 filingsAddress and cadastre registers
Data from official sources, last processed on 13-09-2026. Scores and ratios are computed by Checked and are not a credit decision.